

**Table 4: Comparison of patients with and without progression**

		Progression (MIBC)		p
		No (n=79)	Yes (n=17)	
NLR	Median (IQR)	2,09 (0,99)	2,70 (1,62)	<sup>1</sup> 0,005*
PLR	Median (IQR)	117,2 (60,1)	150,3 (56,9)	<sup>1</sup> 0,001*
SII	Median (IQR)	539,2 (341,9)	817,9 (281,9)	<sup>1</sup> 0,001*
Tumor size	n (%)			
	<30mm	45 (%91,8)	4 (%8,2)	<sup>2</sup> 0,012*
	≥30mm	34 (%72,3)	13 (%27,7)	
Tumor grade	n (%)			
	LG	7 (%77,8)	2 (%22,2)	<sup>3</sup> 0,658
	HG	72 (%82,8)	15 (%17,2)	
CIS	n (%)			
	No	59 (%83,1)	12 (%16,9)	<sup>3</sup> 0,764
	Yes	20 (%80)	5 (%20)	

<sup>1</sup>Mann Whitney U Test<sup>2</sup>Chi-square test<sup>3</sup>Fisher's Exact Test

\*p&lt;0.05

MIBC: Muscle invasive bladder cancer, NLR: Neutrophil lymphocyte ratio, PLR: Platelet lymphocyte ratio, SII: Systemic immune-inflammation index, HG: High-grade, LG: Low-grade, CIS: Carcinoma in situ